


DT04 Rec'd PCT/PTO 07 JUL 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound of Formula I



or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

A is selected from: $-\text{CO}_2\text{H}$, 1*H*-tetrazol-5-yl, $-\text{PO}_3\text{H}_2$, $-\text{PO}_2\text{H}_2$, $-\text{SO}_3\text{H}$, and $-\text{PO}(\text{R}^5)\text{OH}$, wherein R^5 is selected from the group consisting of: C_1 -4alkyl, hydroxy C_1 -4alkyl, phenyl, $-\text{C}(\text{O})-\text{C}_1$ -3alkoxy and $-\text{CH}(\text{OH})$ -phenyl, said phenyl and phenyl portion of $-\text{CH}(\text{OH})$ -phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of: hydroxy, halo, $-\text{CO}_2\text{H}$, C_1 -4alkyl, $-\text{S}(\text{O})_k\text{C}_1$ -3alkyl, wherein k is 0, 1 or 2, C_1 -3alkoxy, C_3 -6 cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C_1 -4alkyl, $-\text{S}(\text{O})_k\text{C}_1$ -3alkyl, C_1 -3alkoxy and C_3 -6 cycloalkoxy optionally substituted with 1-3 halo groups;

n is 2, 3 or 4;

each R^1 and R^2 is each independently selected from the group consisting of: hydrogen, halo, hydroxy, $-\text{CO}_2\text{H}$, C_1 -6alkyl and phenyl, said C_1 -6alkyl and phenyl optionally substituted with 1-3 halo groups;

R^3 is selected from the group consisting of: hydrogen and C_1 -4alkyl, optionally substituted with 1-3 hydroxy or halo groups;

each R^4 is independently selected from the group consisting of: hydroxy, halo, $-CO_2H$, $C_{1-4}alkyl$, $-S(O)_kC_{1-3}alkyl$, wherein k is 0, 1 or 2, $C_{1-3}alkoxy$, C_{3-6} cycloalkoxy, aryl and aralkoxy, the alkyl portions of said $C_{1-4}alkyl$, $-S(O)_kC_{1-3}alkyl$, $C_{1-3}alkoxy$ and C_{3-6} cycloalkoxy optionally substituted with 1-3 halo groups;


C is selected from the group consisting of:

- (1) $C_{1-8}alkyl$, $C_{1-8}alkoxy$, $-(C=O)-C_{1-6}alkyl$ or $-CHOH-C_{1-6}alkyl$, said $C_{1-8}alkyl$, $C_{1-8}alkoxy$, $-(C=O)-C_{1-6}alkyl$ and $-CHOH-C_{1-6}alkyl$ optionally substituted with phenyl, and
- (2) phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, $C_{1-4}alkyl$ and $C_{1-4}alkoxy$, said $C_{1-4}alkyl$ and $C_{1-4}alkoxy$ groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and $C_{1-4}alkyl$, optionally substituted with 1-3 halo groups,

or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: phenyl, $C_{5-16}alkyl$, $C_{5-16}alkenyl$, $C_{5-16}alkynyl$, $-CHOH-C_{4-15}alkyl$, $-CHOH-C_{4-15}alkenyl$, $-CHOH-C_{4-15}alkynyl$, $C_{4-15}alkoxy$, $-O-C_{4-15}alkenyl$, $-O-C_{4-15}alkynyl$, $C_{4-15}alkylthio$, $-S-C_{4-15}alkenyl$, $-S-C_{4-15}alkynyl$, $-CH_2-C_{3-14}alkoxy$, $-CH_2-O-C_{3-14}alkenyl$, $-CH_2-O-C_{3-14}alkynyl$, $-(C=O)-C_{4-15}alkyl$, $-(C=O)-C_{4-15}alkenyl$, $-(C=O)-C_{4-15}alkynyl$, $-(C=O)-O-C_{3-14}alkyl$, $-(C=O)-O-C_{3-14}alkenyl$, $-(C=O)-O-C_{3-14}alkynyl$, $-(C=O)-N(R^6)(R^7)-C_{3-14}alkyl$, $-(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl$, $-(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl$, $-N(R^6)(R^7)-(C=O)-C_{3-14}alkyl$, $-N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl$ and $-N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl$,


when **C** is phenyl or HET then **B** is selected from the group consisting of: $C_{1-6}alkyl$, $C_{1-5}alkoxy$, $-(C=O)-C_{1-5}alkyl$, $-(C=O)-O-C_{1-4}alkyl$, $-(C=O)-N(R^6)(R^7)-C_{1-4}alkyl$,



when **C** is C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl or -CHOH-C₁₋₆alkyl then **B** is phenyl;
and

R⁶ and R⁷ are independently selected from the group consisting of: hydrogen, C₁₋₉alkyl and -(CH₂)_p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C₁₋₃alkyl and C₁₋₃alkoxy, each optionally substituted with 1-3 halo groups.

2. (original) The compound according to Claim 1 wherein HET is selected from the group consisting of:



3. (original) The compound according to Claim 1 wherein n is 2.

4. (original) The compound according to Claim 1 wherein n is 3.

5. (original) The compound according to Claim 3 wherein each R¹ and R² is independently selected from the group consisting of: hydrogen, -CO₂H, hydroxy, halo, C₁₋₃alkyl and phenyl.

6. (original) The compound according to Claim 1 wherein **A** is PO₃H₂.

7. (original) The compound according to Claim 1 wherein **A** is -CO₂H.

8. (original) The compound according to Claim 1 wherein **A** is $\text{PO}(\text{R}^5)\text{OH}$, wherein R^5 is selected from the group consisting of: C_{1-4} alkyl, hydroxy C_{1-4} alkyl, $\text{C}(\text{O})-\text{C}_{1-2}$ alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxy groups.

9. (original) The compound according to Claim 1 wherein **A** is PO_2H_2 .

10. (original) The compound according to Claim 1 wherein **A** is 1*H*-tetrazol-5-yl.

11. (original) The compound according to Claim 1 wherein R^3 is hydrogen or methyl.

12. (original) The compound according to Claim 1 wherein each R^4 is independently selected from the group consisting of: halo, hydroxy, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, phenyl, benzyloxy and cyclopropyloxy.

13. (original) The compound according to Claim 1 wherein **B** is C_{8-10} alkyl and **C** is not present.


14. (original) The compound according to Claim 1 wherein **B** is C_{4-11} alkoxy and **C** is not present.

15. (original) The compound of according to Claim 1 wherein **B** is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4} alkyl and C_{1-4} alkoxy, and **C** is selected from the group consisting of: hydrogen, phenyl, C_{1-8} alkyl, C_{1-8} alkoxy, $-(\text{C}=\text{O})-\text{C}_{1-6}$ alkyl and $-\text{CHOH}-\text{C}_{1-6}$ alkyl, said C_{1-8} alkyl, C_{1-8} alkoxy, $-(\text{C}=\text{O})-\text{C}_{1-6}$ alkyl and $-\text{CHOH}-\text{C}_{1-6}$ alkyl optionally substituted with phenyl.


16. (original) The compound according to Claim 1 wherein **B** is selected from the group consisting of: $-\text{CHOH}-\text{C}_{6-10}$ alkyl, C_{6-10} alkylthio, $-\text{CH}_2-\text{C}_{5-9}$ alkoxy, $-(\text{C}=\text{O})-\text{C}_{6-10}$ alkyl, $-(\text{C}=\text{O})-\text{O}-\text{C}_{5-9}$ alkyl, $-(\text{C}=\text{O})-\text{N}(\text{R}^6)(\text{R}^7)-\text{C}_{5-9}$ alkyl, $-\text{N}(\text{R}^6)(\text{R}^7)-(\text{C}=\text{O})-\text{C}_{5-9}$ alkyl, and **C** is not present.

17. (original) The compound according to Claim 1 wherein **B** is C₁₋₆alkyl or C₁₋₅alkoxy and **C** is phenyl.

18. (original) The compound according to Claim 1 wherein **B-C** is




or



19. (original) The compound according to Claim 1 wherein Ar is phenyl and the group **-B-C** is attached to the phenyl ring at the 3- or 4-position.

20. (original) A compound of Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position;

n is 2, 3 or 4;

each R^1 and R^2 is independently selected from the group consisting of: hydrogen, $-CO_2H$, hydroxy, halo, C_{1-3} alkyl and phenyl, said C_{1-3} alkyl and phenyl optionally substituted with 1-3 halo group;


A is selected from the group consisting of: 1*H*-tetrazol-5-yl, PO_2H_2 , PO_3H_2 , $-CO_2H$ and $PO(R^5)OH$, wherein R^5 is selected from the group consisting of: C_{1-4} alkyl, hydroxy C_{1-4} alkyl, $C(O)-C_{1-2}$ alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxy groups;

R^3 is hydrogen or methyl;


each R^4 is independently selected from the group consisting of: halo, hydroxy, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, phenyl, benzyloxy and cyclopropyloxy; and

B-C is selected from the group consisting of:


- (1) **B** is C_{8-10} alkyl and **C** is not present.
- (2) **B** is C_{4-11} alkoxy and **C** is not present.
- (3) **B** is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4} alkyl and C_{1-4} alkoxy, and **C** is selected from the group consisting of: hydrogen, phenyl, C_{1-8} alkyl, C_{1-8} alkoxy, $-(C=O)-C_{1-6}$ alkyl and $-CHOH-C_{1-6}$ alkyl, said C_{1-8} alkyl, C_{1-8} alkoxy, $-(C=O)-C_{1-6}$ alkyl and $-CHOH-C_{1-6}$ alkyl optionally substituted with phenyl;
- (4) **B** is $-CHOH-C_{6-10}$ alkyl, C_{6-10} alkylthio, $-CH_2-C_{5-9}$ alkoxy, $-(C=O)-C_{6-10}$ alkyl, $-(C=O)-O-C_{5-9}$ alkyl, $-(C=O)-N(R^6)(R^7)-C_{5-9}$ alkyl or $-N(R^6)(R^7)-(C=O)-C_{5-9}$ alkyl, and **C** is not present.
- (5) **B** is C_{1-6} alkyl or C_{1-5} alkoxy and **C** is phenyl.
- (6) **B-C** is





or





21. (original) A compound selected from the group consisting of:
























































22. (currently amended) A method of treating ~~on~~ an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

23 to 33 (canceled).

34. (original) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

35. (original) A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.